Company news
Xencor, Inc. news in 2020
Xencor, Inc.'s news releases, calls and decks from 2020, newest first.
Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer
December 6, 2020
Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
December 5, 2020
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
November 10, 2020
Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
November 8, 2020
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting
November 8, 2020
Xencor Reports Third Quarter 2020 Financial Results
November 4, 2020
Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
November 3, 2020
Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020
October 28, 2020
Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting
October 13, 2020
Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
October 1, 2020
Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
September 8, 2020
Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
September 8, 2020
Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates
September 2, 2020
Xencor Reports Second Quarter 2020 Financial Results
August 3, 2020
Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States
July 30, 2020
Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020
July 27, 2020
Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
July 7, 2020
Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
July 7, 2020
Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
June 21, 2020
Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
May 14, 2020
Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
May 12, 2020
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
May 12, 2020
Xencor Reports First Quarter 2020 Financial Results
May 6, 2020
Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020
April 29, 2020
Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19
March 24, 2020
Xencor Reports Fourth Quarter and Full Year 2019 Financial Results
February 23, 2020
Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020
February 17, 2020
Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
January 7, 2020